Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
复制标题
DOI:
10.1038/clpt.2010.250
复制
发表时间:
2011-01
影响因子:
6.7
通讯作者:
中科院分区:
文献类型:
--
作者:
Major depressive disorder (MDD) is a common psychiatric disease. Selective serotonin reuptake inhibitors (SSRIs) are an important class of drugs used to treat MDD. However, many patients do not respond adequately to SSRI therapy. We used a pharmacometabolomics-informed pharmacogenomic research strategy to identify citalopram/escitalopram treatment outcome biomarkers. Metabolomic assay of plasma samples from 20 escitalopram remitters and 20 non-remitters showed that glycine was negatively associated with treatment outcome (p=0.0054). That observation was pursued by genotyping tag single nucleotide polymorphisms (SNPs) for genes encoding glycine synthesis and degradation enzymes using 529 DNA samples from SSRI-treated MDD patients. The rs10975641 SNP in the glycine dehydrogenase gene was associated with treatment outcome phenotypes. Rs10975641 was then genotyped and was significant (p=0.02) in DNA from 1245 MDD patients in the STAR*D depression study. These results highlight both a possible role for glycine in SSRI response and the use of pharmacometabolomics to “inform” pharmacogenomics.
登录
查看更多内容
影响因子:
11
作者:
Kato, M.;Serretti, A.
通讯作者:
Serretti, A.
影响因子:
1.7
作者:
Mannelli, Paolo;Patkar, Ashwin;Kaddurah-Daouk, Rima
通讯作者:
Kaddurah-Daouk, Rima
影响因子:
9.8
作者:
McMahon, FJ;Buervenich, S;Manji, H
通讯作者:
Manji, H
影响因子:
10.6
作者:
Rush, AJ;Trivedi, MH;Keller, MB
通讯作者:
Keller, MB
影响因子:
5.8
作者:
Barrett, JC;Fry, B;Daly, MJ
通讯作者:
Daly, MJ